Cargando…
DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death
The poor prognosis of ovarian cancer (it is the leading cause of death from gynecological cancers) is mainly due to the acquisition of resistance to carboplatin. Among the possible resistance pathways, resistance to apoptosis and especially the overexpression of inhibitor of apoptosis proteins (IAP)...
Autores principales: | Thibault, Benoît, Genre, Ludivine, Le Naour, Augustin, Broca, Clothilde, Mery, Eliane, Vuagniaux, Grégoire, Delord, Jean Pierre, Wiedemann, Norbert, Couderc, Bettina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294826/ https://www.ncbi.nlm.nih.gov/pubmed/30552344 http://dx.doi.org/10.1038/s41598-018-35860-z |
Ejemplares similares
-
Exploratory window‐of‐opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer
por: Gomez‐Roca, Carlos, et al.
Publicado: (2021) -
The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate
por: Bobardt, Michael, et al.
Publicado: (2019) -
The inhibitor of apoptosis proteins antagonist Debio 1143 promotes the PD-1 blockade-mediated HIV load reduction in blood and tissues of humanized mice
por: Bobardt, Michael, et al.
Publicado: (2020) -
Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model
por: Bellaye, Pierre-Simon, et al.
Publicado: (2018) -
SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells
por: Langdon, Casey G., et al.
Publicado: (2015)